Compositions and methods for treatment of aortic fibrosis
AssigneeVectus Biosystems Pty Limited
InventorKaren Annette DUGGAN
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions comprising vasoactive intestinal peptide (VIP) or fragments thereof, and the use of such compositions in the treatment of aortic fibrosis and other associated conditions.
Claims8
A method of prophylactic or therapeutic treatment of aortic fibrosis in a subject, the method comprising administering to the subject at risk of developing aortic fibrosis, or to a subject having aortic fibrosis, a composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) (SEQ ID NO:1) or one or more functional VIP fragments selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.
A method of reducing collagen formation or enhancing collagen degradation in the aorta of a subject, the method comprising administering to the subject a composition comprising a pharmaceutically effective amount of vasoactive intestine peptide (VIP) (SEQ ID NO:1) or one or more functional VIP fragments selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.
A composition for the prophylactic or therapeutic treatment of aortic fibrosis, the composition comprising a pharmaceutically effective amount of vasoactive intestinal peptide (VIP) (SEQ ID NO:1) or one or more functional VIP fragments selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, or SEQ ID NO:16.
Dependencies are inferred from the claim text.